dc.creator | Salvador-Martín, Sara | es |
dc.creator | Raposo-Gutiérrez, Irene | es |
dc.creator | Navas-López, Víctor Manuel | es |
dc.creator | Gallego-Fernández, Carmen | es |
dc.creator | Moreno-álvarez, Ana | es |
dc.creator | Solar-Boga, Alfonso | es |
dc.creator | Millán Jiménez, Antonio | es |
dc.creator | Merino Bohórquez, Vicente | es |
dc.creator | López-Fernández, Luis A. | es |
dc.date.accessioned | 2023-05-18T09:48:09Z | |
dc.date.available | 2023-05-18T09:48:09Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Salvador-Martín, S., Raposo-Gutiérrez, I., Navas-López, V.M., Gallego-Fernández, C., Moreno-álvarez, A., Solar-Boga, A.,...,López-Fernández, L.A. (2020). Gene signatures of early response to anti-TNF drugs in pediatric inflammatory bowel disease. International Journal of Molecular Sciences, 21 (9), 3364. https://doi.org/10.3390/ijms21093364. | |
dc.identifier.uri | https://hdl.handle.net/11441/146311 | |
dc.description.abstract | Around a 20–30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs can induce and maintain remission in IBD, however, up to 30% of patients do not respond. The aim of the work was to identify markers that would predict an early response to anti-TNF drugs in pediatric patients with IBD. The study population included 43 patients aged <18 years with IBD who started treatment with infliximab or adalimumab. Patients were classified into primary responders (n = 27) and non-responders to anti-TNF therapy (n = 6). Response to treatment could not be analyzed in 10 patients. Response was defined as a decrease in over 15 points in the disease activity indexes from week 0 to week 10 of infliximab treatment or from week 0 to week 26 of adalimumab treatment. The expression profiles of nine genes in total RNA isolated from the whole-blood of pediatric IBD patients taken before biologic administration and after 2 weeks were analyzed using qPCR and the 2−∆∆Ct method. Before initiation and after 2 weeks of treatment the expression of SMAD7 was decreased in patients who were considered as non-responders (p value < 0.05). Changes in expression were also observed for TLR2 at T0 and T2, although that did not reach the level of statistical significance. In addition, the expression of DEFA5 decreased 1.75-fold during the first 2 weeks of anti-TNF treatment in responders, whereas no changes were observed in non-responders. Expression of the SMAD7 gene is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD. TLR2 and DEFA5 need to be validated in larger studies. | es |
dc.format | application/pdf | es |
dc.format.extent | 15 p. | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.relation.ispartof | International Journal of Molecular Sciences, 21 (9), 3364. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Biomarker | es |
dc.subject | Gene expression | es |
dc.subject | Infliximab | es |
dc.subject | Adalimumab | es |
dc.subject | Ulcerative colitis | es |
dc.subject | Crohn’s disease | es |
dc.title | Gene signatures of early response to anti-TNF drugs in pediatric inflammatory bowel disease | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Farmacología, Pediatría y Radiología | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Farmacología | es |
dc.relation.projectID | PEJ16/MED/AI-1260 | es |
dc.relation.projectID | PRE-2018-2 | es |
dc.relation.projectID | PI16/00559; PI19/00792 | es |
dc.relation.publisherversion | https://www.mdpi.com/1422-0067/21/9/3364 | es |
dc.identifier.doi | 10.3390/ijms21093364 | es |
dc.journaltitle | International Journal of Molecular Sciences | es |
dc.publication.volumen | 21 | es |
dc.publication.issue | 9 | es |
dc.publication.initialPage | 3364 | es |
dc.contributor.funder | Consejeria de Educacion y Deporte de la Comunidad de Madrid | es |
dc.contributor.funder | ERDF Funds (FEDER) from the European Commission, "A way of making Europe" | es |
dc.contributor.funder | Gregorio Maranon Health Research Institute | es |
dc.contributor.funder | Instituto de Salud Carlos III | es |